Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 2Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 93Lung Neoplasms 35Meningeal Carcinomatosis 11Neoplasms 10Neoplasm Metastasis 8Colorectal Neoplasms 6Adenocarcinoma of Lung 6Parkinson Disease 4, Autosomal Dominant Lewy Body 4Mesothelioma, Malignant 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Mesothelioma 3Carcinoma 3Advanced Solid Tumors 3Pancreatic Neoplasms 2Non Squamous Non Small Cell Lung Cancer 2Neoplasms by Site 2Neoplasms by Histologic Type 2Endometrial Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Vaccinia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1

Interventions

tislelizumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Non-squamous Non-small-cell Lung Cancer × Pemetrexed × Clear all
NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 3 Recruiting
392 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡